Difference between revisions of "Ancillary testing in prostate cancer"
Jump to navigation
Jump to search
| Line 5: | Line 5: | ||
Molecular panel: | Molecular panel: | ||
*BRCA1 | *[[BRCA1]]. | ||
*BRCA2 | *[[BRCA2]]. | ||
*ATM | *ATM. | ||
*PALB2 | *PALB2. | ||
==See also== | ==See also== | ||
Revision as of 15:10, 1 November 2022
Ancillary testing in prostate cancer is evolving. Prostate cancer panel redirect here.
PARP inhibitors
- Poly(ADP-ribose) polymerases (PARP) inhibitors, e.g. olaparib, target BRCA1/2 mutations.[1]
Molecular panel:
See also
References
- ↑ Dziadkowiec KN, Gąsiorowska E, Nowak-Markwitz E, Jankowska A (December 2016). "PARP inhibitors: review of mechanisms of action and BRCA1/2 mutation targeting". Prz Menopauzalny 15 (4): 215–219. doi:10.5114/pm.2016.65667. PMC 5327624. PMID 28250726. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5327624/.